Yuji Uehara, Medical Oncologist at National Cancer Center Japan, shared a post on X about a paper he co-authored with colleagues published in Lung Cancer Journal:

“Hot off the press Lung Cancer Journal from LC-SCRUM and Thoracic Medical Oncology BIDMC:

Rare EGFR exon 19 insertions (0.1% NSCLC); missed by PCR
2nd-gen EGFR-TKIs most effective
Confirmed by in vitro/in silico.

Great thanks to Susumu Kobayashi.”

“Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry)”

Authors: Yuji Uehara, Hiroki Izumi, Ikei Kobayashi, Susumu Kobayashi, Koichi Goto et al.

Yuji Uehara: TKIs for non-small cell lung cancer with EGFR exon 19 insertions